NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal

Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow by aiming straight for the OTC market with the help of GlaxoSmithKline